IN2012DN02469A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02469A IN2012DN02469A IN2469DEN2012A IN2012DN02469A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A IN 2469DEN2012 A IN2469DEN2012 A IN 2469DEN2012A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disorders
- abnormal
- diseases
- raf
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23807309P | 2009-08-28 | 2009-08-28 | |
| US31303910P | 2010-03-11 | 2010-03-11 | |
| PCT/US2010/046930 WO2011025927A1 (en) | 2009-08-28 | 2010-08-27 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02469A true IN2012DN02469A (de) | 2015-08-21 |
Family
ID=42782253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2469DEN2012 IN2012DN02469A (de) | 2009-08-28 | 2010-08-27 |
Country Status (49)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| EP3028699B1 (de) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf-mutationen für resistenz gegen braf-inhibitoren |
| US8907270B2 (en) | 2010-06-30 | 2014-12-09 | Schlumberger Technology Corporation | Method and apparatus for gain regulation in a gamma detector |
| CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| ES2695099T3 (es) * | 2011-11-23 | 2019-01-02 | Array Biopharma Inc | Formulaciones farmacéuticas |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| WO2013096630A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| EP2831589B1 (de) | 2012-03-28 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | C-raf mutanten, die eine resistenz gegen raf hemmstoffe geben |
| WO2014015054A1 (en) | 2012-07-18 | 2014-01-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| TR201904980T4 (tr) | 2012-08-07 | 2019-05-21 | Novartis Ag | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| US20150232452A1 (en) * | 2012-09-19 | 2015-08-20 | Ruga Corporation | Novel raf kinase inhibitors |
| AU2013343425A1 (en) | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| UA118846C2 (uk) * | 2013-03-21 | 2019-03-25 | Новартіс Аг | Комбінована терапія |
| TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| EP3004060B1 (de) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Verbindungen zur kinasemodulation und indikationen dafür |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| CA3240745A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of erk and raf inhibitors |
| EP3086810A2 (de) * | 2013-12-23 | 2016-11-02 | Novartis AG | Pharmazeutische kombinationen |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (de) | 2014-01-31 | 2019-03-27 | Novartis AG | Antikörpermoleküle mit tim-3 und verwendungen davon |
| DE102015103158A1 (de) | 2014-03-04 | 2015-09-10 | Bergische Universität Wuppertal | Verbindungen für die Behandlung des Melanoms |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| US10428387B2 (en) | 2014-05-16 | 2019-10-01 | University Of Massachusetts | Treating chronic myelogenous leukemia (CML) |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US10167279B2 (en) * | 2014-09-12 | 2019-01-01 | Novartis Ag | Compounds and compositions as RAF kinase inhibitors |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3878465A1 (de) | 2015-07-29 | 2021-09-15 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen tim-3 |
| EP3370768B9 (de) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Spezifisch an pd-1 bindende antikörper und deren verwendung |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| BR112018012981A2 (pt) | 2015-12-30 | 2018-12-04 | Saint Louis University | derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas |
| RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
| MX387795B (es) * | 2016-06-03 | 2025-03-19 | Array Biopharma Inc | Combinaciones farmaceuticas. |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107540699A (zh) * | 2017-10-16 | 2018-01-05 | 康化（上海）新药研发有限公司 | 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法 |
| EP3732285A1 (de) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stammzellkultursysteme für säulenförmige epithelstammzellen und verwendungen davon |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN110256408B (zh) * | 2018-07-12 | 2022-03-22 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
| JP7234418B2 (ja) | 2019-05-16 | 2023-03-07 | イーライ リリー アンド カンパニー | Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ |
| KR20220131229A (ko) | 2019-12-05 | 2022-09-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도 |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| WO2022036176A1 (en) | 2020-08-13 | 2022-02-17 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| AU2021358394A1 (en) | 2020-10-05 | 2023-04-13 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma |
| CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| BR112023025916A2 (pt) | 2021-06-09 | 2024-02-27 | Chugai Pharmaceutical Co Ltd | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção |
| CN114557977A (zh) * | 2022-02-16 | 2022-05-31 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024163166A1 (en) * | 2023-01-30 | 2024-08-08 | 5Metis, Inc. | Boron containing compounds and their uses |
| JPWO2024209717A1 (de) | 2023-04-06 | 2024-10-10 | ||
| CN116396222A (zh) * | 2023-04-10 | 2023-07-07 | 上海睿腾医药科技有限公司 | 一种康奈非尼中间体1-（3-氨基-1-异丙基-1h-吡唑-4-基）乙-1-酮的合成方法 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104250A (en) * | 1976-08-11 | 1978-08-01 | Borg-Warner Corporation | Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents |
| JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
| DE3571974D1 (en) | 1984-12-06 | 1989-09-07 | Pfizer | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| CA2231050A1 (en) | 1995-09-07 | 1997-03-13 | Biovail International Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| AU728701B2 (en) | 1996-05-23 | 2001-01-18 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| PL337020A1 (en) | 1997-05-22 | 2000-07-31 | Searle & Co | Substituted pyrazoles as kinase p38 inhibitors |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| EP2415462A1 (de) | 1999-12-23 | 2012-02-08 | Mayne Pharma International Pty Ltd. | Verbesserte pharmazeutische Zusammensetzungen für schwerlösliche Arzneistoffe |
| AU2001285349A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| IL161462A0 (en) | 2001-10-25 | 2004-09-27 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
| EP1456180B1 (de) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| BRPI0414698A (pt) | 2003-09-23 | 2006-11-28 | Novartis Ag | combinação de um inibidor receptor de vegf com um agente quimioterapêutico |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| EP1706400A1 (de) | 2004-01-09 | 2006-10-04 | Novartis AG | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-aminderivate als igf-ir-inhibitoren |
| JP4688876B2 (ja) | 2004-06-10 | 2011-05-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| RU2007138264A (ru) | 2005-03-17 | 2009-09-10 | Новартис АГ (CH) | N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF |
| US20070099856A1 (en) | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| KR20080037732A (ko) | 2005-08-22 | 2008-04-30 | 노파르티스 아게 | ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물 |
| US20080242667A1 (en) | 2005-08-26 | 2008-10-02 | Smithkline Beecham Corporation | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| EP2024353A2 (de) | 2006-03-16 | 2009-02-18 | Pfizer Products Inc. | Pyrazolverbindungen |
| AU2007234379A1 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| EP2013218A2 (de) * | 2006-04-17 | 2009-01-14 | Arqule, Inc. | Raf-hemmer und ihre verwendung |
| EP2061772A4 (de) | 2006-09-11 | 2011-06-29 | Curis Inc | Multifunktionale kleine moleküle als proliferationshemmende wirkstoffe |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| WO2008042639A1 (en) | 2006-10-02 | 2008-04-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2008045627A2 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| BRPI0807812A2 (pt) | 2007-02-15 | 2020-06-23 | Novartis Ag | Combinações de lbh589 com outros agentes terapêuticos para tratar câncer |
| US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| BRPI0815042A2 (pt) | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
| UA100865C2 (ru) | 2007-10-19 | 2013-02-11 | Эбботт Гмбх Унд Ко. Кг | Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины |
| RU2492170C9 (ru) * | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| AU2009227013B2 (en) * | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| SI2324008T1 (sl) * | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoli kot protein-kinazni inhibitorji |
| JP2011529504A (ja) | 2008-07-28 | 2011-12-08 | ギリアード サイエンシーズ， インコーポレイテッド | シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物 |
| AR073700A1 (es) | 2008-09-29 | 2010-11-24 | Boehringer Ingelheim Int | Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias |
| ES2598178T5 (es) | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| WO2010056662A1 (en) * | 2008-11-11 | 2010-05-20 | University Of Washington | Activated wnt-beta-catenin signaling in melanoma |
| US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| AR075180A1 (es) | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| RU2402602C1 (ru) | 2009-02-12 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| ES2570756T3 (es) * | 2009-06-15 | 2016-05-20 | Nerviano Medical Sciences Srl | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| WO2011092088A1 (en) | 2010-01-27 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2012016993A1 (en) | 2010-08-03 | 2012-02-09 | Nerviano Medical Sciences S.R.L. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| PL2688572T3 (pl) | 2011-03-21 | 2017-08-31 | Valcuria Ab | Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie |
| ES2595407T3 (es) | 2011-06-14 | 2016-12-29 | Novartis Ag | Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa |
| CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| ES2695099T3 (es) | 2011-11-23 | 2019-01-02 | Array Biopharma Inc | Formulaciones farmacéuticas |
| AU2013343425A1 (en) | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| US10576680B2 (en) | 2015-11-19 | 2020-03-03 | The Boeing Company | Modular thermoforming system |
-
2010
- 2010-08-26 JO JOP/2010/0297A patent/JO3002B1/ar active
- 2010-08-26 AR ARP100103123A patent/AR077975A1/es active IP Right Grant
- 2010-08-27 NZ NZ598924A patent/NZ598924A/xx unknown
- 2010-08-27 GE GEAP201012645A patent/GEP20146102B/en unknown
- 2010-08-27 PL PL10748211T patent/PL2470526T3/pl unknown
- 2010-08-27 EA EA201500175A patent/EA201500175A1/ru unknown
- 2010-08-27 LT LTEP14152945.3T patent/LT2727918T/lt unknown
- 2010-08-27 PL PL14152945T patent/PL2727918T3/pl unknown
- 2010-08-27 SM SM20170036T patent/SMT201700036T1/it unknown
- 2010-08-27 EP EP10748211.9A patent/EP2470526B1/de active Active
- 2010-08-27 BR BR112012004453-2A patent/BR112012004453B1/pt active IP Right Grant
- 2010-08-27 DK DK14152945.3T patent/DK2727918T3/da active
- 2010-08-27 KR KR1020127007860A patent/KR101413392B1/ko active Active
- 2010-08-27 WO PCT/US2010/046930 patent/WO2011025927A1/en not_active Ceased
- 2010-08-27 CN CN201080038197.8A patent/CN102725283B/zh active Active
- 2010-08-27 RS RS20140430A patent/RS53489B1/sr unknown
- 2010-08-27 ME MEP-2017-6A patent/ME02684B/de unknown
- 2010-08-27 AU AU2010286569A patent/AU2010286569C1/en active Active
- 2010-08-27 JP JP2012527014A patent/JP5475888B2/ja active Active
- 2010-08-27 PT PT141529453T patent/PT2727918T/pt unknown
- 2010-08-27 ES ES10748211.9T patent/ES2492499T3/es active Active
- 2010-08-27 PT PT107482119T patent/PT2470526E/pt unknown
- 2010-08-27 ES ES14152945.3T patent/ES2610825T3/es active Active
- 2010-08-27 DK DK10748211.9T patent/DK2470526T3/da active
- 2010-08-27 ME MEP-2014-94A patent/ME01860B/me unknown
- 2010-08-27 CN CN201410040923.XA patent/CN103896921B/zh active Active
- 2010-08-27 SI SI201031371A patent/SI2727918T1/sl unknown
- 2010-08-27 MY MYPI2012000611A patent/MY156259A/en unknown
- 2010-08-27 PE PE2012000268A patent/PE20120861A1/es active IP Right Grant
- 2010-08-27 EA EA201200373A patent/EA025222B1/ru not_active IP Right Cessation
- 2010-08-27 SG SG10201405311TA patent/SG10201405311TA/en unknown
- 2010-08-27 US US12/870,130 patent/US8501758B2/en not_active Ceased
- 2010-08-27 CU CU2012000034A patent/CU24110B1/es active IP Right Grant
- 2010-08-27 RS RS20170017A patent/RS55568B1/sr unknown
- 2010-08-27 SG SG2012009304A patent/SG178351A1/en unknown
- 2010-08-27 HU HUE14152945A patent/HUE032847T2/hu unknown
- 2010-08-27 IN IN2469DEN2012 patent/IN2012DN02469A/en unknown
- 2010-08-27 CA CA2771775A patent/CA2771775C/en active Active
- 2010-08-27 HR HRP20140799AT patent/HRP20140799T1/hr unknown
- 2010-08-27 SI SI201030711T patent/SI2470526T1/sl unknown
- 2010-08-27 UA UAA201203042A patent/UA112285C2/uk unknown
- 2010-08-27 MX MX2012002546A patent/MX2012002546A/es active IP Right Grant
- 2010-08-27 EP EP14152945.3A patent/EP2727918B1/de active Active
- 2010-08-27 UY UY0001032860A patent/UY32860A/es active IP Right Grant
-
2012
- 2012-02-09 CL CL2012000340A patent/CL2012000340A1/es unknown
- 2012-02-13 IL IL218084A patent/IL218084A/en active IP Right Grant
- 2012-02-17 TN TNP2012000081A patent/TN2012000081A1/en unknown
- 2012-02-24 CO CO12032570A patent/CO6612222A2/es active IP Right Grant
- 2012-02-24 NI NI201200029A patent/NI201200029A/es unknown
- 2012-02-24 DO DO2012000051A patent/DOP2012000051A/es unknown
- 2012-02-27 GT GT201200053A patent/GT201200053A/es unknown
- 2012-02-27 HN HN2012000441A patent/HN2012000441A/es unknown
- 2012-02-28 CR CR20120102A patent/CR20120102A/es unknown
- 2012-02-28 EC ECSP12011700 patent/ECSP12011700A/es unknown
- 2012-03-19 ZA ZA2012/02020A patent/ZA201202020B/en unknown
- 2012-03-23 MA MA34716A patent/MA33604B1/fr unknown
-
2013
- 2013-06-28 US US13/931,111 patent/US9314464B2/en active Active
-
2014
- 2014-02-06 JP JP2014021339A patent/JP6045519B2/ja active Active
- 2014-09-12 SM SM201400133T patent/SMT201400133B/xx unknown
-
2016
- 2016-01-13 US US14/994,827 patent/US9593100B2/en active Active
- 2016-01-13 US US14/994,710 patent/US9593099B2/en active Active
- 2016-03-15 US US15/070,905 patent/US10005761B2/en active Active
- 2016-06-10 US US15/179,644 patent/US9850230B2/en active Active
- 2016-06-10 US US15/179,385 patent/US9850229B2/en active Active
-
2017
- 2017-01-03 HR HRP20170005TT patent/HRP20170005T1/hr unknown
- 2017-01-10 CY CY20171100028T patent/CY1118452T1/el unknown
- 2017-01-19 SM SM201700036T patent/SMT201700036B/it unknown
- 2017-11-20 US US15/818,082 patent/US10576080B2/en active Active
- 2017-11-20 US US15/818,264 patent/US10568884B2/en active Active
-
2019
- 2019-02-12 LU LU00102C patent/LUC00102I2/fr unknown
- 2019-02-12 LU LU00101C patent/LUC00101I2/fr unknown
- 2019-03-01 HU HUS1900013C patent/HUS1900013I1/hu unknown
- 2019-03-01 HU HUS1900012C patent/HUS1900012I1/hu unknown
- 2019-03-05 NO NO2019011C patent/NO2019011I1/no unknown
- 2019-03-05 NO NO2019012C patent/NO2019012I1/no unknown
- 2019-03-07 LT LTPA2019005C patent/LTC2470526I2/lt unknown
- 2019-03-07 LT LTPA2019006C patent/LTPA2019006I1/lt unknown
- 2019-03-15 NL NL300973C patent/NL300973I2/nl unknown
- 2019-03-18 CY CY2019014C patent/CY2019014I1/el unknown
- 2019-03-18 CY CY2019013C patent/CY2019013I1/el unknown
-
2020
- 2020-01-14 US US16/741,937 patent/US20200323852A1/en not_active Abandoned
-
2021
- 2021-07-15 US US17/376,199 patent/USRE49556E1/en active Active
-
2022
- 2022-04-20 US US17/724,589 patent/US20230116233A1/en not_active Abandoned
-
2023
- 2023-01-27 EC ECSENADI20234573A patent/ECSP23004573A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02469A (de) | ||
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| IN2012DN02471A (de) | ||
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
| MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| IN2012DN01961A (de) | ||
| MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MY172151A (en) | Certain chemical entities, compositions and methods | |
| MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
| DE602006016449D1 (de) | ||
| WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity |